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Abstract One of the long-term goals of mutagenesis
programs in the mouse has been to generate mutant lines to
facilitate the functional study of every mammalian gene.
With a combination of complementary genetic approaches
and advances in technology, this aim is slowly becoming a
reality. One of the most important features of this strategy
is the ability to identify and compare a number of muta-
tions in the same gene, an allelic series. With the advent of
gene-driven screening of mutant archives, the search for a
specific series of interest is now a practical option. This
review focuses on the analysis of multiple mutations from
chemical mutagenesis projects in a wide variety of genes
and the valuable functional information that has been ob-
tained from these studies. Although gene knockouts and
transgenics will continue to be an important resource to
ascertain gene function, with a significant proportion of
human diseases caused by point mutations, identifying an
allelic series is becoming an equally efficient route to
generating clinically relevant and functionally important
mouse models.
Introduction
A fundamental aim of biology is not only to identify the
normal function of genes but also to understand their role
in human disease when mutated or otherwise abnormally
affected. To this end, the mouse continues to be the model
organism of choice in many cases because of extensive
comparative analysis of its completed genome, the avail-
ability of an increasing number of genetic manipulation
techniques, and the ability to perform physiologic and
behavioral tests that can be extrapolated directly to human
phenotypic traits. In addition to individual research groups
examining single genes, a commitment has been made in
recent years to the systematic generation of mouse mutants
on a large scale using various forward genetics strategies in
both whole organisms and embryonic stem (ES) cells.
Despite these considerable efforts, over 70% of mamma-
lian genes still do not have a corresponding mutant line;
however, this so-called ‘‘phenotype gap’’ is beginning to
close as these projects continue, establishing a large and
valuable catalog of inherited traits, their causative muta-
tions, and importantly, multiple alleles representing each
one for comparative analysis.
Gene knockouts and the KOMP project
One way to study gene function at the level of the whole
organism is by examining the consequences of its inacti-
vation. This may be achieved either by ‘‘knocking out’’ the
relevant promoter or coding sequences, or by ‘‘knocking
in’’ an inactivating point mutation, deletion, or truncation
to disrupt the activity of the corresponding product. With a
number of strategies available, including gene targeting by
homologous, site-specific, or transpositional recombina-
tion, gene trapping, and RNA-mediated interference,
knockout technology constitutes the most widely used ap-
proach to create loss-of-function alleles in model organ-
isms (Chen and Soriano 2003; Kuznetsov 2003; Sangiuolo
and Novelli 2004). The exploitation of inducible promoters
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and tissue-specific recombinase enzymes also allows the
deletion of a gene of interest in a particular organ, cell type,
and/or stage of development; such conditional and tissue-
specific knockouts provide more accurate and finely tuned
systems to study gene function than those generated by
conventional constitutive technology (Porret et al. 2006). A
combination of these approaches, in addition to the gen-
eration of multiple gene knockouts, has revolutionized the
study of many fields of fundamental research, most sig-
nificantly impacting developmental biology with major
insights into the physiology of the hematopoietic, immune,
skeletal, cardiovascular, and nervous systems (Shastry
1998; Sheahan et al. 2004; Ning et al. 2006).
Equally important, as technical advances in mapping
and mutation screening have facilitated the rapid identifi-
cation of genetic defects related to human disorders, tar-
geted mutagenesis in the mouse has become an invaluable
tool to model and gain mechanistic insights into the
pathology and progression of these conditions. For exam-
ple, disruption of the insulin receptor substrate-2 gene has
produced a good biochemical model for type-2 diabetes
(LeRoith and Gavrilova 2006). In addition constitutive
heterozygous and conditional knockouts deficient for a
variety of tumor suppressor genes faithfully recapitulate
many of the clinical symptoms present in the correspond-
ing human cancer predisposition syndromes, including
Brca1+/– and Brca2+/– mice for familial breast cancer or
Ptc1+/– mice for basal cell nevus syndrome (Ghebranious
and Donehower 1998; Hakem and Mak 2001; Pazzaglia
2006). Other successes of disease modeling in the mouse
from which programs of gene therapy have been initiated
notably include Cftr-deficient mice for cystic fibrosis
(Rosenecker et al. 2006; Snouwaert et al. 1992). These and
many other knockouts have provided ideal preclinical
models for diagnostic development, drug discovery, and
targeted therapy testing (Walke et al. 2001; Zambrowicz
and Sands 2003).
Although existing knockouts account for almost half
(12,000) of the known genes in the mouse genome, only
20% have been described in the literature and/or reported
in public databases such as the Mouse Knockout &
Mutation Database (http://www.research.bmn.com/mkmd)
or the Mouse Genome Database (http://www.informat-
ics.jax.org). With the advent of fully annotated mouse and
human genome sequences and only about 15,000 genes
remaining to be disrupted, the National Institutes of Health
(NIH) has recently launched the Knockout Mouse Project
(KOMP), a $52 million cooperative program over five
years to generate a comprehensive public resource of sys-
tematic knockout mutations of the mouse genome in ES
cells by gene targeting (http://www.nih.gov/science/mod-
els/mouse/knockout) (Austin et al. 2004). Each year
approximately 500 new ES cell lines will be selected by a
peer-review process for production of the corresponding
knockout mice, reporter tissue expression analysis, and
basic phenotyping. Depending on the findings, a number of
those will undergo further characterization, including more
detailed and specialized phenotyping and tissue profiling.
Complementary high-throughput approaches have been
applied to ES cell insertional mutagenesis, or gene trap-
ping, and recent technological advances have extended the
scope and value of this method to the generation of con-
ditional knockout alleles in addition to targeted mutagen-
esis (Branda and Dymecki 2004; Cobellis et al. 2005).
Recently, two major programs have been established,
EUCOMM (http://www.eucomm.org) and norCOMM
(http://www.norcomm.phenogenomics.ca/index.htm), with
the aim of generating over 30,000 new conditional gene-
trap ES cell lines for analysis. In addition, these projects
aim to collate and distribute compatible tissue-specific Cre
recombinase lines in parallel and therefore represent a
powerful resource for the selection of a desired gene
knockout. By centralizing the rapid and efficient produc-
tion of mouse knockouts and gene-trap lines and making
them readily available to the entire scientific community,
such large-scale programs will not only save considerable
time and money but also will provide the basis for nor-
malization of comparative phenotypic studies.
The seemingly perfect mouse knockout technology,
however, also comes with its limitations and pitfalls. In
many instances null embryos are not viable due to devel-
opmental defects, precluding the functional study of these
genes at later stages of development and in the adult. This
particularly applies to knockout mice of tumor suppressors
which, with few exceptions, all show embryonic lethality
with a distinctive pattern of organ malformations (Ghe-
branious and Donehower 1998). Although these mice have
provided good models for the study of individual genes in
embryonic development and the regulation of differentia-
tion, apoptosis, and cell cycle control during organogenesis
(Shastry, 1998), they have not necessarily been useful for
the characterization of gene function in tumorigenesis. The
development of conditional and tissue-specific gene-defi-
ciency technologies mentioned above, however, has now
overcome this restriction.
While mouse knockouts generally do provide very
valuable information about the function of a gene in vivo, a
number of reports have raised legitimate concerns as to
their true value as models of human disease (Ho-
chgeschwender and Brennan 1995; Routtenberg 1995);
knockout mice often fail to recapitulate the expected
clinical symptoms, sometimes producing totally unex-
pected, conflicting, subtle, or absent phenotypes (Elsea and
Lucas 2002). Moreover, although most mouse genes do
perform functions identical to their human homologs, the
physiologic differences between these species may greatly
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influence the phenotypic outcome. This may notably ac-
count for differences in tissue specificity; prominent
examples include p53- and Rb-deficient mice whose tumor
spectrum considerably differs from that seen in patients
with Li-Fraumeni and inherited childhood retinoblastoma,
respectively (Ghebranious and Donehower 1998). Another
common pitfall of gene targeting is the potential disruption
of transcriptional control elements that govern the expres-
sion of neighboring genes by the introduction of a selection
marker from the targeting vector. This likely explains why
very different phenotypes have been obtained from the
disruption of the same gene using different vectors.
(Gingrich and Hen 2000; Olson et al. 1996). A number of
reports have also highlighted the fact that the strategies
used for gene inactivation are not equivalent. To study the
role of phosphoinositide 3-kinase c (PI3Kc) in cardiac
function, deficient mice were generated either by using a
traditional knockout strategy or by knocking in a targeted
mutation that causes loss of kinase function. Surprisingly,
these mice displayed different phenotypes with PI3Kc
knockout mice showing reduced inflammatory responses
and increased cardiac contractility, while the mutant PI3Kc
knockin mouse retained only the immunologic defect.
Molecular studies later revealed that PI3Kc also functions
as a scaffolding protein, thus transducing both kinase
activity-dependent and -independent signaling pathways
(Patrucco et al. 2004). This demonstrates that different
functions of a gene may be revealed depending on the
region that is inactivated.
Finally, regardless of the engineering strategy or model
organism used, one major risk associated with the complete
loss of function of a given gene is the establishment of
compensatory mechanisms that may—at least par-
tially—mask the effect of its inactivation. For example,
despite the essential role of myoglobin in oxygen transport
from erythrocytes to mitochondria, myoglobin knockout
mice show normal cardiac function (Garry et al. 1998).
Further studies revealed that more than half of null em-
bryos die in utero and that those surviving have developed
adaptative mechanisms to compensate for the defect in
oxygen transfer (Meeson et al. 2001). In that respect,
conditional knockout models offer another advantage over
their constitutive counterparts as adaptive responses are
unlikely to take place shortly after the knockout event. The
lack of overt phenotype is especially frequent when the
gene of interest belongs to a family of related proteins with
some functional redundancy, and in many cases it may be
necessary to create animals carrying null alleles of two or
more members to obtain informative phenotypes (Kono
et al. 2004).
Knockout technology has become an invaluable exper-
imental tool for assigning gene function and modeling
genetic disorders in vivo. However, it must be used with
caution and some of the examples mentioned above high-
light the fundamental problem posed by using genetic
deficiency regarding the validity and phenotypic interpre-
tation of knockout models; the studies are often limited to
examining the compensatory effects of gene ablation as
opposed to changes in the function of the gene of interest.
Therefore, to address complex questions regarding gene
function and regulation, complementary approaches that
alter gene structure in a more subtle way must be used in
conjunction with knockout technology, such as the analysis
of single-point mutations and their phenotypic conse-
quences. Such strategies may therefore be limited to the
modeling of single-gene disorders as opposed to complex
traits or mitochondrial or chromosomal disorders; however,
approximately 10% of all human genes are currently
implicated in monogenic Mendelian diseases, and this
number continues to rise (Antonarakis and Beckmann
2006; Hamosh et al. 2005). Moreover, at the time of
writing over two thirds of the 2300 disease genes in the
Human Gene Mutation Database contain point mutations
(http://www.hgmd.cf.ac.uk/ac/index.php) (Stenson et al.
2003). In addition, the fact that 75% of disorders in man are
inherited in a dominant manner (McKusick 1998) indicates
that both dominant and recessive mouse point mutants are
vital to complement targeted knockouts and provide the
most clinically relevant disease models.
Phenotype- and genotype-driven approaches to
generating allelic mouse mutants
Before the advent of molecular biology, many important
discoveries were derived from mutations that arrived
spontaneously in inbred mouse colonies. However, to
generate significant numbers of mutant mice more effi-
ciently, a number of large-scale N-ethyl-N-nitrosourea
(ENU) mutagenesis programs were instigated ten years ago
(Brown and Peters 1996; Hrabe de Angelis et al. 2000;
Nolan et al. 2000). Their success led to the establishment of
over a dozen independent centers worldwide, each with
particular skills and interests and with the aim to stan-
dardize procedures and share resources (summarized in
Table 1 in Cordes 2005). Details of these strategies and
variations in the breeding schemes have been reviewed
extensively elsewhere (Brown and Balling 2001; Hrabe de
Angelis and Balling 1998; Justice 2000). Initially, these
centers have concentrated on a phenotype-driven approach,
in which mutant progeny are screened for abnormalities
using a simple yet quantitative assessment of physiology
and behavior in combination with more focused pheno-
typing methods for a specific trait or organ of interest
(Keays and Nolan 2003; Rogers et al. 1997; Thaung et al.
2002). Once inheritance of the phenotype is confimed,
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Table 1 Examples of characterized allelic series (>3 members) generated by ENU mutagenesis
Gene No. of sequenced
ENU mutants
Type of mutations References




DNA-binding protein 7 (Chd7)
9 6 nonsense Kiernan et al. 2002;
Bosman et al. 20053 splicing
Type IV procollagen a1 (Col4a1) 9 9 missense Favor et al. 2007
Type IV procollagen a2 (Col4a2) 3 3 missense Favor et al. 2007
Gamma-E crystallin (Cryge) 4 2 missense Graw et al. 2001, 2002, 2004
1 splicing
1 disruption of start codon,
novel protein expressed
Dystrophin (Dmd) 4 1 nonsense Im et al. 1996
3 splicing
Enamelin (Enam) 3 2 missense Masuya et al. 2007
1 splicing
Glucokinase (Gk) 12 7 missense Inoue et al. 2004; Toye et al. 2004
2 nonsense
3 splicing
Glucose phosphatase isomerase (Gpi1) 4 3 missense Pearce et al. 1995
1 splicing
G protein-coupled receptor 33 (Gpr33) 5 5 missense Grosse et al. 2006
cGMP-phosphodiesterase 6b (Pde6b) 7 2 missense Thaung et al. 2002;
Hart et al. 20053 nonsense
2 splicing
Lactate dehydrogenase (Ldh1) 5 4 missense Sandulache et al. 1994;
Pretsch et al. 19981 splicing
Melanocortin-3 receptor (Mc3r) 3 3 missense Grosse et al. 2006
Malnocortin-4 receptor (Mc4r) 7 7 missense Grosse et al. 2006;
Meehan et al. 2006
Mammal-fish-conserved-sequence 1 (MFSC1) 3 3 missense Masuya et al. 2007
Myosin-Va (Myo5a) 10 8 missense Huang et al. 1998a, 1998b
2 splicing
Myosin-VIIa (Myo7a) 4 1 missense Mburu et al. 1997
2 nonsense
1 splicing
Paired box gene 6 (Pax6) 14 4 missense Favor 1983, 1986;
Favor and Neuhauser-Klaus 2000;
Favor et al. 2001;
Thaung et al. 2002;




1 disruption of Kozak sequence
Peripheral myelin protein 22 (Pmp22) 3 2 missense Isaacs et al. 2000, 2002
1 nonsense
Quaking QKI protein (Qk) 3 (plus 2
unknown)
2 missense Justice and Bode 1988;
Noveroske et al. 20051 splicing
Sodium channel Nav1.6 (Scn8a) 3 3 missense Buchner et al. 2004
Mothers against decapentaplegic, drosophila,
homolog of, 4 (Smad4)
4 2 missense Vivian et al. 2002;
Chen et al. 20062 splicing
Triosephosphatase isomerase (Tpi) 4 3 missense Zingg et al. 1995
1 nonsense
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mutant lines of interest are then analyzed in more detail
and the causative mutation is identified by positional
cloning.
One advantage of this approach over targeted muta-
genesis is it can create a range of mutations: hypomorphic
(reduced amount of gene product), hypermorphic (in-
creased amount of gene product), and neomorphic (altered
function) alleles, in addition to those that are null (loss of
function), facilitating the identification of novel functions
for known genes. Such a phenomenon was recently illus-
trated by our own studies where the identification of a
stabilizing gain-of-function point mutation in the mixed-
lineage leukemia fusion partner Af4, the cause for the
neurodegeneration in the ataxic mouse mutant robotic,
revealed a new role for this gene in the central nervous
system otherwise unpredictable from the phenotypic pre-
sentation of the Af4 knockout mouse (Bitoun and Davies
2005; Bitoun et al. 2007; Isnard et al. 2000; Isaacs et al.
2003; Oliver et al. 2004).
The random nature of ENU also means that mutiple
mutations in the same gene, an allelic series, may occur in
independent lines. A combination of such mutants is
therefore more likely to provide information related to gene
dosage, or the identification of functionally important
protein interacting domains, than a classical gene knock-
out. This may be particularly applicable to the pharma-
ceutical industry, because typically the mode of action of
drugs is to alter the activity of proteins rather than elimi-
nate their function, or to target specific residues of an ac-
tive site, for example (Russ et al. 2002). Alternatively, a
knockin of the desired mutation might provide a suitable
genetic model; however, the time and cost constraints of
generating one or more mutant lines using this method is
often prohibitive. An engineered mutant trangene might
provide a more rapid solution, although studies of trans-
genic lines are often confounded by factors such as epitope
tags, multiple insertions, incorrect promoter artifacts, or
position effects that do not influence ENU point mutations
that have the advantage of always occurring at the en-
dogneous genomic position. Consequently, an ENU
mutation that is not known to be causative in human dis-
ease is still likely to provide valuable insights into gene
function.
However, the practicalities of large-scale phenotype-
driven mouse mutagenesis, such as the limitation and bias
of the phenotyping methods, means that many potentially
interesting or subtle phenotypes may simply not be de-
tected in a first-pass screen; consequently, mutagenesis
centers routinely cryopreserve tissues from each new mu-
tant line for future rederivation and genotyping regardless
of the phenotypic data obtained (Glenister and Thornton
2000). These resources, in combination with recent ad-
vances in the rapid detection of mutations by denaturing
high-performance liquid chromatography (DHPLC) (Dob-
son-Stone et al. 2000) and temperature gradient capillary
electrophoresis (TGCE) (Culiat et al. 2005; Sakuraba et al.
2005), have made it practical to use a gene-driven approach
to mouse mutant detection. Here, a gene of interest can be
efficiently screened for mutations by PCR from thousands
of individual DNA samples followed by rederivation of the
selected lines for further study (Coghill et al. 2002; Mi-
chaud et al. 2005). This technique is also applicable to ES
cells that are amenable to random chemical mutagenesis
and PCR screening (Chen et al. 2000; Munroe et al. 2004).
Although there is no guarantee of any measureable phe-
notype in the resulting mutant, it has been calculated from
pilot studies that 5000 DNA samples is sufficient to iden-
tify at least two alleles with 90% confidence (Coghill et al.
2002; Quwailid et al. 2004). Such values are based on
estimating the proportion of the genome that is protein
coding; therefore, assuming no positional bias in the
mutagenic action of ENU, the larger the gene, the greater
the likelihood of identifying a new mutation (Concepcion
et al. 2004). With the size of these archives increasing and
other academic centers such as RIKEN generating similar
resources (Sakuraba et al. 2005), gene-driven screening
will play an increasingly important role in the identification
of multiple mutant alleles. Another, sometimes overlooked,
advantage of such strategies is that all the resulting mutants
from a particular ENU screen will be derived from the
same genetic background, a vital feature for comparative
assessment. It is well known that inbred lines differ con-
siderably in a large number of physiologic and behavioral
parameters (Contet et al. 2001; Kaku et al. 1988; Solberg
et al. 2006), which may confound attempts to accurately
compare spontaneous mutant or knockout lines on different
backgrounds (Lalouette et al. 1998; Runkel et al. 2004).
Allelic series in mouse: genotype-phenotype
correlations
Historically, the first large collections of allelic series were
derived from early genetic studies that analyzed the off-
spring of mutagenized male mice with females homozy-
gous for a mutation that causes a visible phenotype such as
coat color. These specific locus tests were not only used to
titrate the effectiveness of particular mutagens accurately,
but they also generated dozens of alleles at these particular
loci, such as dilute and short-ear (Davis and Justice 1998a,
1998b). There are also numerous examples of allelic
spontaneous mutants, although these are, as expected,
biased toward visible phenotypes such as gait dysfunction
(Lalouette et al. 1998; Letts et al. 2003). There is now an
increasing number of mutiple mutant alleles representing
individual genes; a range of the more recent examples that
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have used large-scale mutagenesis are outlined in Table 1.
Although not an exhausative list, some of those that have
highlighted the various experimental features of this
method and have provided the most interesting functional
insights are decribed below.
Pmp22: insights into human peripheral neuropathies
The random nature of ENU as a mutagen provides a sound
basis for the discovery of novel disease models; however,
in a phenotype-driven screen there will naturally be a bias
toward those defects that are early onset, easy to recognize,
and nonlethal. Some of the earliest examples of an allelic
series identified from a large-scale ENU screen are the
three Trembler mutants Trm1H, Trm2H, and Trm3H. These
dominant mutants displayed a range of resting tremor and
hind-limb grasping behavior, with Trm1H the most severely
affected and Trm3H the least (Isaacs et al. 2000, 2002).
Quantitative histopathologic analysis revealed that there
was a direct correlation between the severity of the phe-
notype and the level of hypomyelination in the peripheral
nerve of the mutant mice; Trm1H displayed the fewest and
most narrowed axonal profiles and the greatest increase in
endoneurial connective tissue of all the lines. The causative
mutations were identified in peripheral myelin protein 22
(Pmp22), a highly conserved structural component of the
axonal myelin sheath already implicated in peripheral
neuropathies in humans (Isaacs et al. 2000, 2002). The
Trm1H mutation (H12R) is in an identical position as an
amino acid substitution described in a patient suffering
from Derjerine-Sottas syndrome (DSS), a severe demyle-
linating neuropathy (Valentijn et al. 1995). In addition, the
Ser72 altered in the relatively mild Trm3H line is a putative
hotspot for PMP22 mutations that relate to the same dis-
order (Marques et al. 1998, 2004). This serine-to-threonine
change is far more conservative than the four human
mutations documented at the same residue in DSS patients,
suggesting a strong association between genotype and
phenotype. Interestingly, this can also be applied to two
spontaneous Pmp22 mutants; the Pmp22-Tr mutation
causes a severe tremor in mice and occurs in another
conserved position altered in DSS patients (Ionasescu et al.
1997; Suter et al. 1992), whereas the less severe Charcot-
Marie-Tooth disease type 1A (CMT1A) can be caused by
identical mutations found in the milder Tr-J mutant (Va-
lentijn et al. 1992). The Pmp22 knockout also displays
resting tremor and hypomyelination, although the pheno-
type is less severe than Tr or Trm1H, suggesting that the
disease progression is not simply due to a loss-of-function
effect (Adlkofer et al. 1995). Indeed, in vitro modeling
experiments proposed that expression of mutant Pmp22
caused retention of wild-type protein away from the
membrane (Colby et al. 2000). Importantly, similar
experiments with the three ENU lines showed there was a
direct relationship between the severity of the phenotype
and the propensity of Pmp22 to form oligomers in vitro
(Isaacs et al. 2002). The allelic series of Pmp22 mutants
has therefore provided valuable insight into the genotype-
phenotype correlation of peripheral neuropathies in hu-
mans.
Gk: modeling multiple human mutations in new
diabetes models
Inactivating mutations in glucokinase (GK), a critical
glycolysis enzyme and ‘‘glucose sensor’’ in insulin
secreting b cells, are known to cause dominant maturity-
onset diabetes of the young type 2 (MODY2) and recessive
permanent neonatal diabetes mellitus (PNDM) (Njolstad
et al. 2001; Vionnet et al. 1992). Mouse Gk knockout
models have provided some insight into disease-causing
mechanisms, although they have not revealed details of the
structure-function relationships of this important metabolic
protein (Postic et al. 1999). Moreover, over 190 missense,
nonsense, and splicing mutations in GK have been de-
scribed in MODY2 alone, suggesting that similar genetic
lesions in mice would provide the most clinically relevant
information (Gloyn 2003). Two independent groups have
combined large-scale ENU mutagenesis with a biochemi-
cal screening approach to identify new mouse models of
diabetes and have identified a total of 12 Gk mutations with
distinct enzyme properties and hyperglycemic phenotypes
(Inoue et al. 2004; Toye et al. 2004). For example, Inoue
et al. demonstrated that three of their missense mutations
(M-272, M-341, and M-392) caused a marked reduction in
GK activity, hyperglycemia, and glucose intolerance, al-
though only two of these (M-272 and M-341) showed a
corresponding reduction in protein level, suggesting that
Gk mutations can cause protein instabilty in addition to
directly affecting the function of the enzyme (M-392).
Another point mutation (M-210) occurred at the splice
donor site of the b-cell-specific exon 1, causing a similar
hyperglycemic phenotype and confirming that disruption of
this isoform is sufficient to impair glucose regulation as
observed in b-cell-specific Gk knockout mice (Postic et al.
1999). This allelic series also demonstrated that the degree
of severity is significantly influenced by the position of the
Gk mutation if homozygous. Severe hyperglycemia in M-
210 homozygous mutant pups was first detectable at
postnatal day 2 (P2), in addition to marked growth retar-
dation, liver abnormalities, and eventual death by P7. By
contrast, the M-392 point mutation produced a milder
hyperglycemic phenotype when homozygous, with no
overt growth retardation or liver defects (Inoue et al. 2004).
The differing phenotypes are related to the relative position
of the mutations; M-210 homozygous mice have a phe-
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notype similar to Gk knockouts, whereas the M-392
mutation occurs in the glucose-binding region as opposed
to the more functionally significant catalytic domain (Gidh-
Jain et al. 1993). Importantly, four of the newly identified
Gk mutations, including the b-cell-specific substiution, are
identical to those found in humans (Gloyn 2003); the
missense mutation (M-236) at Thr288 is not only identical
to mutations found in both MODY2 and PNDM patients,
but it is situated in the active site of GK, correlating di-
rectly with the reported significant reduction in kinase
activity of the enzyme (Davis et al. 1999; Gidh-Jain et al.
1993). These new mutants have provided a detailed
structure-function study of GK and the relationship be-
tween varying levels of its inactivation to hyperglycemic
phenotypes that are directly relevant to both dominant and
recessive forms of diabetes.
Quaking: functional analysis of protein isoforms
The RNA binding protein encoded by the quaking loci
mediates the stabilty and splicing of oligodendrocyte RNA
transcripts such as myelin basic protein (MBP) and exists
in three distinct isforms: QKI-5, -6, and -7 (Wu et al.
2002). A total of five ENU-induced mutants have since
been identified by their failure to complement the original
spontaneous qkv/qkv line: four that are homozygous
embryonic lethal (qkkt1m, qkk2, qkkt3/4, and qkl-1) and a
single viable allele (qke5) that causes seizures in the second
postnatal week in addition to adult-onset progressive ataxia
(Justice and Bode 1988; Noveroske et al. 2005). In addition
to demonstrating an unexpected developmental role for this
gene, subtle yet significant differences in the embryonic
phenotypes of the four lethal lines have revealed new
information regarding the functional domains of the QKI
isoforms. For example, the qkk2 mutation causes death at
embryonic day (E) 8.5-11.5 due to a disorganization of the
anterior-posterior (A-P) axis, in addition to cranial and
heart defects (Justice and Bode 1988). The causative
mutation appears to be inherited in a semidominant manner
and occurs at a highly conserved amino acid in the RNA-
binding (KH) domain common to all three QKI isoforms
(Cox et al. 1999). In contrast, a splice site is disrupted in
the recessive qkl-1 mutant, leading to a loss of the QKI-5
protein and cessation of development between E8.0 and
E9.0, suggesting that disruption of the nuclear isoform is
sufficient to cause embryonic lethality (Cox et al. 1999;
Justice and Bode 1988). Despite the viability of qke5/qke5
mice, severe dysmyelination of the brain is evident, in
addition to the presence of axonal swellings in the cere-
bellum that are likely to account for the observed ataxia.
Expression studies revealed that the QKI-6 and -7 isoforms
are not present in mutant postnatal oligodendrocytes and
levels of QKI-5 are considerably reduced, although all
three isoforms appear to be expressed at normal levels in
astrocytes (Noveroske et al. 2005). Because no coding
mutations in the quaking loci were identified, this evidence
points to disruption of an as-yet unidentified tissue-specific
regulatory region. Further examination showed that mark-
ers of mature oligodendrocytes were disrupted in qke5/qke5
mice, suggesting that the severe phenotype is due to
defective myelination by QKI-regulated pathways rather
than to aberant development of these cells during prolif-
eration. The biological importance of the qke5 mutant is
also emphasized by the fact that the original viable qkv line
contains a large deletion that disrupts two additional genes
that are likely to influence the demyelination phenotype
(Lorenzetti et al. 2004). This ENU-derived allelic series
has not only revealed a new role for quaking in embryonic
vasculogenesis, but it has also demonstrated that regulation
of the gene is critical for normal CNS myelination; these
mutants are a useful resource for modeling seizure and
neural tube defects in addition to psychiatric disorders such
as schizophrenia to which human QKI has recently been
associated (Haroutunian et al. 2006).
Pde6b: new models of retinal degeneration
From a phenotype-driven screen of over 6000 ENU mu-
tants for vision defects detectable by either microscopy or
visual tracking response, 25 inherited phenotypes were
isolated, with 7 of these caused by mutations in Pde6b, a
gene previously implicated in eye pathophysiology
(Thaung et al. 2002). Mutations in the b subunit of the rod
cGMP-phosphodiesterase (PDE6B) gene have been shown
to account for approximately 2% of cases of retinitis pig-
mentosa (RP), causing degeneration of the retina and
blindness (McLaughlin et al. 1995). Mice homozygous for
the null Pde6b allele (Pde6brd1) provide a model for
autosomal recessive (ar) RP, but suffer from almost com-
plete photoreceptor apoptotic degeneration by three weeks
of age due to persistent opening of cGMP-gated cation
channels (Chang et al. 1993). Consequently, a Pde6b allelic
series containing mutants with slower disease onset would
be more practical as a tool for analyzing potential thera-
peutic strategies. Four of the novel recessive mutants
identified (Pde6brd1-1-4H) displayed essentially identical
phenotypes to the endogenous Pde6brd1 alleles of the C3H
mouse strain; however, the remaining lines showed varying
degrees of post-weaning-onset atypical retinal degeneration
(atrd), named Pde6batrd1-3 (Hart et al. 2005; Thaung et al.
2002). As expected from their related pathology to
Pde6brd1 mice, the four Pde6b1-4H mutants contained
mutations that are predicted to cause loss of function: three
generated premature stop codons and the fourth altered a
highly conserved splice donor site. Interestingly, the latter
mutation is identical to one found in a patient with arRP,
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once again correlating ENU mutants with aberant human
alleles (McLaughlin et al. 1995). Of the three less severe
alleles, two mutations (Pde6batrd1 and Pde6batrd3) were in
the catalytic domain of Pde6b and the third (Pde6batrd2)
occurred in another splice donor site. Molecular analysis of
Pde6batrd2 transcripts showed that the predominant product
was truncated and presumably nonfunctional, although
17% of the transcripts analyzed were correctly spliced and
expressed, presumably accounting for the milder retinal
degeneration seen in this mutant line compared to rd1 mice
(Hart et al. 2005). Combined visual acuity, fundus, and
histopathologic analysis of the three atrd lines showed that
Pde6batrd1 displays the least severe phenotype; this may
reflect the fact that in related phosphodiesterases the mu-
tated histidine is replaced by a tyrosine, indicating that this
residue is not necessarily functionally essential. By con-
trast, the asparagine mutated in Pde6batrd3 mice is con-
served in all known mammalian phosphodiesterases, and
this is reflected in a reduced visual acuity performance
compared with those homozygous for the Pde6batrd1 allele
(Hart et al. 2005). The strong genotype-phenotype corre-
lation in this study has shed new light on the functional
domains of Pde6b as well as provide valuable new models
for RP and related disorders.
Smad4: ES cell-derived gene-driven screening
Whereas gene-driven screens from whole-animal archives
have proved to be successful, the initial cost and space
involved in generating thousands of lines may be prohibi-
tive (Williams et al. 2003). Consequently, a number of
groups have established mutagenized ES cell libraries for
PCR screening and subsequent recovery (Chen et al. 2000;
Munroe et al. 2004). The validity of this approach has been
demonstrated by the identification of 29 Smad2 and Smad4
mutations in a screen of over 2000 ENU-mutagenized ES
cell clones (Vivian et al. 2002). Both genes, transducers of
transforming growth factor b (TGF-b) superfamily sig-
naling, have been implicated in the development of human
cancers (Miyaki and Kuroki 2003), although the peri-
gastrulation lethality of knockouts has limited research into
their role in late embryonic stages or adult life (Weinstein
et al. 2000). A series of Smad4 mutants was recovered and,
unexpectedly, three of these lines, Smadm1Mag, Smadm2Mag,
and Smadm3Mag, were viable in the homozygous state and
displayed no detectable phenotype in adults despite mis-
sense substitutions in three conserved residues spread
throughout the protein. The Smad4m4Mag mutation, how-
ever, occurred in a splice donor site, causing the deletion of
an exon and the generation of a truncated protein with 19
additional out-of-frame amino acids. Homozygous
Smad4m4Mag mutants, unsurprisingly, did not survive
embryogenesis and failed to initiate gastrulation. Interest-
ingly, ES cells heterozygous for the mutation showed
steady-state Smad4 protein levels considerably lower than
expected, suggesting that the mutant protein may confer
instability to wild-type Smad4 (Vivian et al. 2002). This
was confirmed by further biochemical analysis that dem-
onstrated that the truncated protein is not only targeted for
proteosomal degradation but can form a complex with
wild-type Smad4, targeting it for proteolysis (Chen et al.
2006). This pilot study illustrates that although an ES-cell
gene-driven approach can be used to generate allelic series,
because of the random nature of the mutagen not all new
lines may have a functional effect on the gene of interest.
The MFCS1 element: mutation analysis of a regulatory
region
While the vast majority of gene-driven screens have con-
centrated on exonic and splice site regions, the method can
equally be applied to any genomic sequence. A recent
study has screened a short, well-characterized cis-acting
element, Mammal-fish-conserved-sequence 1 (MFCS1),
which regulates the expression of the polarity-signaling
protein Sonic hedgehog (Shh) (Masuya et al. 2007). In
humans there are a number of cases of preaxial polydactyly
(PPD) caused by point mutations in MFCS1 (Lettice et al.
2003; Maas and Fallon 2005); however, no molecular
motifs have been discovered in this region that explain the
mechanisms involved in Shh regulation by an element
situated over 1 Mb upstream of the coding region (Lettice
et al. 2002). From over 3500 mutant mice screened, three
new mutations were discovered, M101116, M101117, and
M101192, flanking the pre-existing PPD ENU mutant
M100081 (Sagai et al. 2004). M101117 and M101192
showed no limb dismorphology, whereas the remaining
lines had a semidominant PPD phenotype, with M100081
also showing tibial hemimelia when in the homozygous
state. Ectopic expression of Shh was detected in the ante-
rior region of the hind-limb bud of M100081 and M101116
homozygotes at E10.5, which was confirmed by transgenic
analysis of embryos generated with the LacZ reporter gene
under the control of mutated MFCS1. As expected, the
level of ectopic Shh expression correlated with the relative
severity of the PDD phenotype, but also with the evolu-
tionary conservation of the mutated nucleotide; the
M100081 and M101116 substitutions occur at positions
found in fugu, whereas the nucleotide positions altered in
the less severe M10117 and M101192 lines are conserved
only as far as chicken. The molecular mechanisms con-
trolling these observations remain unclear and may relate
to aberrant binding of transcription factors. However, this
study highlights the power of this strategy to identify novel
features of regulatory elements, a natural progression from
the current mutation analysis of protein-coding domains.
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Conclusions and future prospects
The cost of generating a new allelic series is continually
decreasing with advances in DNA analysis and the
expansion of mutant mouse archives. For example, com-
bining TGCE with over 17,000 mutant genomic DNA
samples, Ingenium Pharmaceuticals state they are able to
generate at least five new alleles for any given gene and
provide live adult mutant mice within three to four months
(Augustin et al. 2005). With this number of novel strains
available, preselection of the most biologically relevant
mutations will become routine and necessary in many cases
(Grosse et al. 2006). Improvements in ES cell technology
have also enhanced the efficiency of gene-driven screens
from mutagenized stem cell archives. Recovery of these
lines has traditionally relied on introducing ES cells into
blastocycts, followed by two rounds of breeding to gener-
ate mice homozygous for the desired mutation. Hybrid ES
cell lines and tetraploid host embryos can facilitate the
identification of phenotypes in the first generation (F0),
although this method suffers from a number of confound-
ing technical inefficiencies that preclude its use as a high-
throughput strategy. The latest advance uses laser-assisted
injection of ES cells into eight-cell-stage embryos, gener-
ating viable F0 mice of both sexes that are nearly 100%
chimeric. A pilot study demonstrated that the phenotype of
previously characterized mutations could be successfully
recapitulated in mice recovered from ES cells using this
method (Poueymirou et al. 2007). It has even been possible
to identify and successfully rederive new splice variants
from a highly pooled archive of 40,000 mutagenized ES
cell clones using nested exon-skipping PCR primers
(Greber et al. 2005). Because the time and cost of these
high-thoughput technologies is decreasing, the availability
of an ‘‘off-the-shelf’’ series of mutations for a given gene
is slowly becoming a reality.
It must not be overlooked, however, that each new ENU
mutant line harbors many other mutations in addition to the
one that may have been identified by gene-driven screening
(Hitotsumachi et al. 1985). The estimate that one functional
animo acid change is obtained every 1.82 Mb of coding
DNA was determined from a gene-based screen of the
Harwell ENU archive (Quwailid et al. 2004). Consequently
it was calculated that there is still a 7% chance that a
second confounding mutation is linked to the originally
identified loci after ten generations of backcrossing to a
wild-type strain (Keays et al. 2006). Marker-assisted
selection (MAS), in which offspring with the smallest
amount of donor chromosome linked to the mutation of
interest are used for breeding, can be used to circumvent
this problem (Visscher et al. 1996). Although this may
detract from the apparent speed and convenience of a gene-
driven approach, additional experimental evidence such as
a BAC rescue (Keays et al. 2007) or even a second allelic
mutation (Hafezparast et al. 2003) can provide sufficient
supporting evidence that a novel genetic lesion is causa-
tive.
As the studies above have illustrated, multiple-mutant
alleles frequently provide valuable insight into gene func-
tion, including unexpected and serendipitous findings, as a
consequence of the random nature of ENU mutagenesis.
The power of this technique relies on evolutionary con-
servation of DNA sequence and physiologic parameters to
extrapolate conclusions to human disease states; conse-
quently, the mouse will continue to provide important and
clinically relevant phenotypes. Moreover, there is likely to
be a move toward mutation screening of non-protein-cod-
ing regions such as promoter elements, introns, and non-
coding RNAs as more is learned about their role in biology.
For example, the modeling of human point mutations in the
noncoding RMRP RNA has provided new insight into the
role of this component of the ribonucleoprotein complex in
cartilage-hair hypoplasia (Hermanns et al. 2005). There is
no doubt, therefore, that large-scale chemical mutagenesis,
in combination with other genetic tools such as conven-
tional and conditional knockouts, knockins, and transgenics
will continue to play a vital role in the generation of new
therapeutic targets.
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